ImmunityBio (NASDAQ: IBRX) reported Q2 2026 ANKTIVA revenue of $50.7 million, representing 92% year-over-year growth and marking its eighth consecutive quarter of revenue growth. The company also advanced its regulatory pipeline with an FDA PDUFA date of January 6, 2027, expanded approvals in the UAE, and expects multiple regulatory and clinical milestones over the next 12 months. Sector: Biotechnology / Immunotherapy Key Highlights 💰 ANKTIVA revenue reached $50.7 million, up 92% YoY 📈 Achieved eight consecutive quarters of revenue growth 📅 FDA PDUFA date set for January 6, 2027 🌍 Expanded UAE regulatory approvals 🔬 Multiple regulatory and clinical milestones expected over the next 12 months Why It Matters Strong commercial growth and continued regulatory progress reinforce ImmunityBio's momentum as it expands ANKTIVA's global presence and advances its immunotherapy pipeline. Read More: https://www.thinksabio.com/reports/isr/IBRX